Literature DB >> 24695740

Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.

Xiaorong Gu1, Zhenbo Hu1, Quteba Ebrahem1, John S Crabb2, Reda Z Mahfouz1, Tomas Radivoyevitch3, John W Crabb2, Yogen Saunthararajah4.   

Abstract

Gene activation requires cooperative assembly of multiprotein transcription factor-coregulator complexes. Disruption to cooperative assemblage could underlie repression of tumor suppressor genes in leukemia cells. Mechanisms of cooperation and its disruption were therefore examined for PU.1 and RUNX1, transcription factors that cooperate to activate hematopoietic differentiation genes. PU.1 is highly expressed in leukemia cells, whereas RUNX1 is frequently inactivated by mutation or translocation. Thus, coregulator interactions of Pu.1 were examined by immunoprecipitation coupled with tandem mass spectrometry/Western blot in wild-type and Runx1-deficient hematopoietic cells. In wild-type cells, the NuAT and Baf families of coactivators coimmunoprecipitated with Pu.1. Runx1 deficiency produced a striking switch to Pu.1 interaction with the Dnmt1, Sin3A, Nurd, CoRest, and B-Wich corepressor families. Corepressors of the Polycomb family, which are frequently inactivated by mutation or deletion in myeloid leukemia, did not interact with Pu.1. The most significant gene ontology association of Runx1-Pu.1 co-bound genes was with macrophages, therefore, functional consequences of altered corepressor/coactivator exchange were examined at Mcsfr, a key macrophage differentiation gene. In chromatin immunoprecipitation analyses, high level Pu.1 binding to the Mcsfr promoter was not decreased by Runx1 deficiency. However, the Pu.1-driven shift from histone repression to activation marks at this locus, and terminal macrophage differentiation, were substantially diminished. DNMT1 inhibition, but not Polycomb inhibition, in RUNX1-translocated leukemia cells induced terminal differentiation. Thus, RUNX1 and PU.1 cooperate to exchange corepressors for coactivators, and the specific corepressors recruited to PU.1 as a consequence of RUNX1 deficiency could be rational targets for leukemia differentiation therapy.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Chromatin Modifying Enzymes; Enhanceosome; Enzyme Inhibitors; Epigenetics; Leukemogenesis; Protein Complexes; Protein Interactome; Transcription Coactivators; Transcription Regulation; Transcription Repressor

Mesh:

Substances:

Year:  2014        PMID: 24695740      PMCID: PMC4031539          DOI: 10.1074/jbc.M114.562447

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Cooperative and antagonistic interplay between PU.1 and GATA-2 in the specification of myeloid cell fates.

Authors:  Jonathan C Walsh; Rodney P DeKoter; Hyun Jun Lee; Erica D Smith; David W Lancki; Michael F Gurish; Daniel S Friend; Richard L Stevens; John Anastasi; Harinder Singh
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Polycomb segment myeloid malignancies.

Authors:  Yogen Saunthararajah; Jaroslaw Maciejewski
Journal:  Blood       Date:  2012-02-02       Impact factor: 22.113

3.  CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter.

Authors:  D E Zhang; C J Hetherington; S Meyers; K L Rhoades; C J Larson; H M Chen; S W Hiebert; D G Tenen
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

4.  p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.

Authors:  K P Ng; Q Ebrahem; S Negrotto; R Z Mahfouz; K A Link; Z Hu; X Gu; A Advani; M Kalaycio; R Sobecks; M Sekeres; E Copelan; T Radivoyevitch; J Maciejewski; J C Mulloy; Y Saunthararajah
Journal:  Leukemia       Date:  2011-06-24       Impact factor: 11.528

5.  Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains.

Authors:  Jennifer J Trowbridge; Amit U Sinha; Nan Zhu; Mingjie Li; Scott A Armstrong; Stuart H Orkin
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

6.  Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.

Authors:  J Wang; Y Saunthararajah; R L Redner; J M Liu
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

Review 7.  Deconstructing repression: evolving models of co-repressor action.

Authors:  Valentina Perissi; Kristen Jepsen; Christopher K Glass; Michael G Rosenfeld
Journal:  Nat Rev Genet       Date:  2010-02       Impact factor: 53.242

8.  Cooperation between the GATA and RUNX factors Serpent and Lozenge during Drosophila hematopoiesis.

Authors:  Lucas Waltzer; Géraldine Ferjoux; Laetitia Bataillé; Marc Haenlin
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

9.  Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development.

Authors:  Hui Huang; Ming Yu; Thomas E Akie; Tyler B Moran; Andrew J Woo; Nathan Tu; Zachary Waldon; Yin Yin Lin; Hanno Steen; Alan B Cantor
Journal:  Mol Cell Biol       Date:  2009-05-26       Impact factor: 4.272

10.  Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.

Authors:  A Ptasinska; S A Assi; D Mannari; S R James; D Williamson; J Dunne; M Hoogenkamp; M Wu; M Care; H McNeill; P Cauchy; M Cullen; R M Tooze; D G Tenen; B D Young; P N Cockerill; D R Westhead; O Heidenreich; C Bonifer
Journal:  Leukemia       Date:  2012-02-20       Impact factor: 11.528

View more
  19 in total

Review 1.  Fetal Hemoglobin Induction by Epigenetic Drugs.

Authors:  Donald Lavelle; James Douglas Engel; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2018-04-22       Impact factor: 3.851

2.  GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition.

Authors:  Francis O Enane; Wai Ho Shuen; Xiaorong Gu; Ebrahem Quteba; Bartlomiej Przychodzen; Hideki Makishima; Juraj Bodo; Joanna Ng; Chit Lai Chee; Rebecca Ba; Lip Seng Koh; Janice Lim; Rachael Cheong; Marissa Teo; Zhenbo Hu; Kwok Peng Ng; Jaroslaw Maciejewski; Tomas Radivoyevitch; Alexander Chung; London Lucien Ooi; Yu Meng Tan; Peng-Chung Cheow; Pierce Chow; Chung Yip Chan; Kiat Hon Lim; Lisa Yerian; Eric Hsi; Han Chong Toh; Yogen Saunthararajah
Journal:  J Clin Invest       Date:  2017-07-31       Impact factor: 14.808

3.  Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.

Authors:  Yogen Saunthararajah; Mikkael Sekeres; Anjali Advani; Reda Mahfouz; Lisa Durkin; Tomas Radivoyevitch; Ricki Englehaupt; Joy Juersivich; Kathleen Cooper; Holleh Husseinzadeh; Bartlomiej Przychodzen; Matthew Rump; Sean Hobson; Marc Earl; Ronald Sobecks; Robert Dean; Frederic Reu; Ramon Tiu; Betty Hamilton; Edward Copelan; Alan Lichtin; Eric Hsi; Matt Kalaycio; Jaroslaw Maciejewski
Journal:  J Clin Invest       Date:  2015-01-26       Impact factor: 14.808

Review 4.  The RUNX1-PU.1 axis in the control of hematopoiesis.

Authors:  Maria Rosaria Imperato; Pierre Cauchy; Nadine Obier; Constanze Bonifer
Journal:  Int J Hematol       Date:  2015-03-08       Impact factor: 2.490

Review 5.  Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance.

Authors:  Valery Adorno-Cruz; Golam Kibria; Xia Liu; Mary Doherty; Damian J Junk; Dongyin Guan; Chris Hubert; Monica Venere; Erin Mulkearns-Hubert; Maksim Sinyuk; Alvaro Alvarado; Arnold I Caplan; Jeremy Rich; Stanton L Gerson; Justin Lathia; Huiping Liu
Journal:  Cancer Res       Date:  2015-01-20       Impact factor: 12.701

6.  Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.

Authors:  Xiaorong Gu; Quteba Ebrahem; Reda Z Mahfouz; Metis Hasipek; Francis Enane; Tomas Radivoyevitch; Nicolas Rapin; Bartlomiej Przychodzen; Zhenbo Hu; Ramesh Balusu; Claudiu V Cotta; David Wald; Christian Argueta; Yosef Landesman; Maria Paola Martelli; Brunangelo Falini; Hetty Carraway; Bo T Porse; Jaroslaw Maciejewski; Babal K Jha; Yogen Saunthararajah
Journal:  J Clin Invest       Date:  2018-07-17       Impact factor: 14.808

7.  A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.

Authors:  Brian Hill; Deepa Jagadeesh; Brad Pohlman; Robert Dean; Neetha Parameswaran; Joel Chen; Tomas Radivoyevitch; Ashley Morrison; Sherry Fada; Meredith Dever; Shelley Robinson; Daniel Lindner; Mitchell Smith; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2020-12-14       Impact factor: 3.851

8.  Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells.

Authors:  Babal K Jha; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2020-12-14       Impact factor: 3.851

9.  Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells.

Authors:  Francis O Enane; Yogen Saunthararajah; Murray Korc
Journal:  Cell Death Dis       Date:  2018-09-06       Impact factor: 8.469

10.  The Genome-Wide Binding Profile for Human RE1 Silencing Transcription Factor Unveils a Unique Genetic Circuitry in Hippocampus.

Authors:  James C McGann; Michael A Spinner; Saurabh K Garg; Karin A Mullendorff; Randall L Woltjer; Gail Mandel
Journal:  J Neurosci       Date:  2021-07-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.